Key facts
- Notable investors include Hubei Gaotou Huimeng Venture Capital Management.
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Maitong Innovation Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Maitong Innovation Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Maitong Innovation Pharmaceutical
Developer of targeted anti-tumor small-molecule drugs intended for patients and clinical programs targeting glioma, AML, cholangiocarcinoma, and related cancers. The company is engaged in the research and development of small-molecule targeted anti-cancer drugs focused on tumor metabolic enzyme targets, thereby enabling clients with advanced targeted oncology therapies addressing cancers such as glioma, acute myeloid leukemia, and cholangiocarcinoma.
- Sector
- Healthcare
- HQ
- Huangshi, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Maitong Innovation Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Maitong Innovation Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Maitong Innovation Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.